Cadaver nerve allografts can provide similar advantages as autologous nerve graft while minimizing the donor site morbidity of nerve autograft. However, the use of cadaver nerve allograft requires temporary systemic immunosuppression, which can increase the risk of infection after surgery and has limited the use of these grafts clinically. The efforts to eliminate immunosuppression led to the development of processed (or acellular) nerve allografts (PNAs), which have gained popularity as an alternative to nerve autograft in the recent years. PNAs are processed cadaver nerves that remove immunogenic cellular components but retain the highly organized extracellular matrix to provide ideal scaffolding structure for nerve regeneration, thereby eliminating the need for immunosuppression.
Since the introduction of the PNAs, there are a few multicenter studies that have been published in the literature evaluating their efficacy. Notably, in 2008, a multicenter observational registry study (RANGER) was started; the first publication from this registry was released in 2012 by Brooks et al.
26 In this study, the nerve gap length was 5 to 50 mm and stratified into three different groups (5 to 14 mm, 15 to 29 mm, and 30 to 50 mm). The meaningful recovery was defined as S3-S4 or M3-M5 on the MacKinnon modification of the Medical Research Council grading system. In the 5- to 14-mm group, 100% had meaningful recovery, whereas the 15- to 29-mm group had a 76% meaningful recovery rate and the 30- to 50-mm group had a 91% meaningful recovery rate. When stratified by type of nerve repair, meaningful recovery was observed in 89% of sensory, 86% of motor, and 77% of mixed nerve repairs. When analyzed based on mechanism of injury, meaningful recovery was seen in 89% of the laceration group, 88% of the neuroma group, and 82% of the complex group (blast injury, avulsion, crush, compression, and gunshot wound). In 2020, a follow-up study by Safa et al
27 reported meaningful recovery of 82% for nerve gap up to 70 mm. This study showed similar findings in the repair of different nerve types when compared with the study by Brooks et al
26 (meaningful recovery 84%, 83%, and 71% for sensory, motor, and mixed nerve repairs, respectively). In the nerve gap subanalysis, the new study added another category of nerve gap, 50 to 70 mm. Meaningful recovery rates for less than 15 mm, 15 to 29 mm, and 30 to 49 mm were 91%, 85%, and 78%, respectively, and they were not significantly different. The meaningful recovery was significantly better in the less than 15-mm group when compared with the 50- to 70-mm group (91% versus 60%,
P = 0.011). However, the 50- to 70-mm group had more complex injury than the less than 15-mm group. Of note, the RECON study, which is a multicenter prospective randomized subject and evaluator blinded comparative study of manufactured conduits and PNAs, has completed its enrollment and has met its primary end point required to officially apply for a biologics license application with the FDA.